as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹6,505.0
Change
-86.0 (-1.3%)
Open
₹6,600.0
Prev. Close
₹6,591.0
Day High
₹6,705.0
Day Low
₹6,444.0
Volume Analysis
Traded
6,164
Delivered
3,264
Delivery %
52.95%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹6,919.66 | ₹6,812.33 | ₹6,658.66 | ₹6,551.33 | ₹6,397.66 | ₹6,290.33 | ₹6,136.66 |
| Fibonacci | ₹6,812.33 | ₹6,712.63 | ₹6,651.03 | ₹6,551.33 | ₹6,451.63 | ₹6,390.03 | ₹6,290.33 |
| Camarilla | ₹6,576.78 | ₹6,552.85 | ₹6,528.93 | ₹6,551.33 | ₹6,481.08 | ₹6,457.15 | ₹6,433.23 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-25.89%
1 Week
-2.18%
1 Month
-8.46%
3 Months
-20.93%
6 Months
-17.15%
1 Year
-26.18%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Company Overview
Sector
Healthcare
Source: Screener.in (Consolidated figures) — data as of 25 Sep 2026. Not investment advice.
TopFund Analysis
Astrazeneca Pharma Ind Lt holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 67/100. The strongest factor is Risk & Volatility (94/100), while Liquidity (42/100) is the weakest area to weigh before deciding.
TopFund Score — Fundamentals Quality
67/100 — GoodData confidence: 60/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Corporate Governance
Institutional Ownership
Risk & Volatility
Liquidity
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
ROC imposed Rs.1.88 lakh penalty on AstraZeneca Pharma and Rs.50,000 each on former officers for delayed MR-2 filing.
Dr. Sandeep Arora resigns as Director-Medical Affairs, effective September 15, 2026.
Crisil ESG Ratings assigned AstraZeneca Pharma India an ESG score of 64 for FY2026.
Delhi High Court stayed NPPA overcharging demand on Betaloc-50 until February 10, 2027, with 15% deposit.
Source: BSE regulatory filings, via Screener.in.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 19.89% | 19.57% | 18.5% | 17.21% | 17.02% | 16.85% | 17.45% | 17.41% | 17.0% | 16.73% | 16.42% | 16.24% |
| Promoters | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% | 75.0% |
| FII | 2.69% | 2.66% | 2.73% | 2.79% | 2.9% | 2.92% | 2.89% | 3.03% | 2.74% | 2.71% | 2.78% | 2.68% |
| DII | 2.42% | 2.76% | 3.77% | 4.99% | 5.08% | 5.21% | 4.65% | 4.55% | 5.26% | 5.55% | 5.79% | 6.08% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Astrazeneca Pharma Ind Lt (this stock) | — | — | — | — |
| Sun Pharmaceutical Ind L | 444,405 | 35.2 | 5.32 | 16.0% |
| Divi S Laboratories Ltd | 255,487 | 85.8 | 15.25 | 16.5% |
| Torrent Pharmaceuticals L | 189,746 | 85.0 | 20.11 | 27.4% |
| Apollo Hospitals Enter. L | 128,055 | 60.9 | 13.51 | 21.2% |
| Zydus Lifesciences Ltd | 120,089 | 24.7 | 4.48 | 21.2% |
| Cipla Ltd | 111,060 | 31.0 | 3.23 | 11.6% |
Which Mutual Funds Hold Astrazeneca Pharma Ind Lt?
Frequently Asked Questions about Astrazeneca Pharma Ind Lt
Astrazeneca Pharma Ind Lt (ASTRAZEN) closed at ₹6,505.0 on NSE on 25 September 2026, down 86.0 (1.3%) from the previous close.
Astrazeneca Pharma Ind Lt trades on the NSE (National Stock Exchange of India) under the symbol ASTRAZEN.
Astrazeneca Pharma Ind Lt has a TopFund Quality Score of 67/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Astrazeneca Pharma Ind Lt?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.